GAO Downgrades Rating of FDA’s Action Plans for Postmarket Drug Monitoring and Shortages

In its latest biennial report to Congress on high-risk government programs, the GAO downgraded its rating of the FDA’s action plans, saying CDER, CBER and CDRH’s long-term strategies lack adequate details and performance measures.
Source: Drug Industry Daily